Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
D. Alarcón-Segovia, D.G. Alarcón.
Pleuro-pulmonary manifestations of systemic lupus erythematosus.
Drugs Made Ger, 39 (1961), pp. 7-17
[2.]
L. Prokunina, C. Castillejo-López, F. Oberg, I. Gunnarsson, L. Berg, V. Magnusson, et al.
A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans.
Nat Genet, 32 (2002), pp. 666-669
[3.]
D. Alarcón-Segovia, J.W. Worthington, L.E. Ward, K.G. Wakim.
Lupus diathesis and the hydralazine syndrome.
N Engl J Med, 272 (1965), pp. 462-466
[4.]
D. Alarcón-Segovia, K.G. Wakim, J.W. Worthington, L.E. Ward.
Clinical and experimental studies on the hydralazine syndrome and its relationship to systemic lupus erythematosus.
Medicine (Baltimore), 46 (1967), pp. 1-33
[6.]
D. Alarcón-Segovia, E. Fishbein, V.M. Betancourt.
Antibodies to nucleoprotein and to hydrazide-altered soluble nucleoprotein in tuberculous patients receiving isoniazid.
Clin Exp Immunol, 5 (1969), pp. 429-437
[7.]
D. Alarcón-Segovia, E. Fishbein, H. Alcala.
Isoniazid acetylation rate and development of antinuclear antibodies upon isoniazid treatment.
Arthritis Rheum, 14 (1971), pp. 748-752
[8.]
D. Alarcón-Segovia, A.L. Brown Jr.
Classification and etiologic aspects of necrotizing angiitides: an analytic approach to a confused subject with a critical review of the evidence for hypersensitivity in polyarteritis nodosa.
Mayo Clin Proc, 39 (1964), pp. 205-222
[10.]
D. Alarcón-Segovia, E. Fishbein, H. Alcalá, E. Olguin-Palacios, S. Estrada-Parra.
The range and specificity of antinuclear antibodies in systemic lupus erythematosus.
Clin Exp Immunol, 6 (1970), pp. 557-571
[11.]
D. Alarcón-Segovia, E. Fishbein, E. García-Ortigoza, S. Estrada-Parra.
Uracil-specific anti-RNA antibodies in scleroderma.
Lancet, 1 (1975), pp. 363-366
[12.]
D. Alarcón-Segovia, E. Fishbein.
Immunochemical characterization of the anti-RNA antibodies found in scleroderma and systemic lupus erythematosus. I. Differences in reactivity with Poly (U) and Poly-(A) Poly (U).
J Immunol, 115 (1975), pp. 28-31
[13.]
D. Alarcón-Segovia, J. Ruiz-Gómez, E. Fishbein, M.E. Bustamante.
Interferon production by lymphocytes from patients with systemic lupus erythematosus.
Arthritis Rheum, 17 (1974), pp. 590-592
[14.]
D. Alarcón-Segovia.
Symptomatic Sjogren's syndrome in mixed connective tissue disease.
J Rheumatol, 3 (1976), pp. 191-195
[15.]
D. Alarcón-Segovia.
Mixed connective tissue disease: a disorder of immune regulation.
Semin Arthritis Rheum, 13 (1983), pp. 114-120
[16.]
D. Alarcón-Segovia, M.H. Cardiel.
Comparison between 3 diagnostic criteria for mixed connective tissue disease. Study of 593 patients.
J Rheumatol, 16 (1989), pp. 328-334
[17.]
D. Alarcón-Segovia.
Mixed connective tissue disease - a decade of growing pains.
J Rheumatol, 8 (1981), pp. 535-540
[18.]
D. Alarcón-Segovia, A. Ruiz-Arguelles, E. Fishbein.
Antibody to nuclear ribonucleoprotein penetrates live human mononuclear cells through Fc receptors.
Nature, 271 (1978), pp. 67-69
[19.]
D. Alarcón-Segovia, A. Ruiz-Arguelles.
Decreased circulating thymus-derived cells with receptors for the Fc portion of immunoglobulin G in systemic lupus erythematosus.
J Clin Invest, 62 (1978), pp. 1390-1394
[20.]
D. Alarcón-Segovia, A. Ruiz-Arguelles.
Suppressor cell loss and dysfunction in mixed connective tissue disease.
Arthritis Rheum, 23 (1980), pp. 314-318
[21.]
R. Palacios, L. Llorente, D. Alarcón-Segovia, A. Ruiz-Arguelles, E. Díaz-Jouanen.
Autologous rosette-forming T cells as the responding cells in human autologous mixed-lymphocyte reaction.
J Clin Invest, 65 (1980), pp. 1527-1530
[22.]
A. Ruiz-Arguelles, D. Alarcón-Segovia, L. Llorente, J.A. Del Giudice-Knipping.
Heterogeneity of the spontaneously expanded and mitogen-induced generation of suppressor cell function of T cells on B cells in systemic lupus erythematosus.
Arthritis Rheum, 23 (1980), pp. 1004-1009
[23.]
R. Palacios, D. Alarcón-Segovia, L. Llorente, A. Ruiz-Arguelles, E. Díaz-Jouanen.
Human post-thymic precursor cells in health and disease. I. Characterization of the autologous rosette-forming T cells as post-thymic precursors.
Immunology, 42 (1981), pp. 127-135
[24.]
D. Alarcón-Segovia, F. Ramos-Niembro, G. Ibanez de Kasep, J. Alcocer, R.P. Tamayo.
Long-term evaluation of colchicine in the treatment of scleroderma.
J Rheumatol, 6 (1979), pp. 705-712
[25.]
J. Alcocer-Varela, D. Alarcón-Segovia.
Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus.
J Clin Invest, 69 (1982), pp. 1388-1392
[26.]
L. Llorente, W. Zou, Y. Levy, Y. Richaud-Patin, J. Wijdenes, J. Alcocer-Varela, et al.
Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus.
J Exp Med, 181 (1995), pp. 839-844
[27.]
D. Alarcón-Segovia, J. Sánchez-Guerrero.
Primary antiphospholipid syndrome.
J Rheumatol, 16 (1989), pp. 482-488
[28.]
D. Alarcón-Segovia, M.E. Pérez-Vázquez, A.R. Villa, C. Drenkard, J. Cabiedes.
Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus.
Semin Arthritis Rheum, 21 (1992), pp. 275-286
[29.]
J. Cabiedes, A.R. Cabral, D. Alarcón Segovia.
Clinical manifestations of the anti-phospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-beta 2-glycoprotein-I than with antiphospholipid antibodies.
J Rheumatol, 22 (1995), pp. 1899-1906
[30.]
A.R. Cabral, J. Cabiedes, D. Alarcón-Segovia.
Antibodies to phospholipidfree beta 2-glycoprotein-I in patients with primary antiphospholipid syndrome.
J Rheumatol, 22 (1995), pp. 1894-1898
[31.]
A.R. Cabral, M.C. Amigo, J. Cabiedes, D. Alarcón-Segovia.
The antiphospholipid/cofactor syndromes: a primary variant with antibodies to beta 2- glycoprotein-I but no antibodies detectable in standard antiphospholipid assays.
Am J Med, 101 (1996), pp. 472-481
[32.]
G. Vargas-Alarcón, A. García, S. Bahena, H. Melin-Aldana, F. Andrade, G. Ibanez-de-Kasep, et al.
HLA-B alleles and complotypes in Mexican patients with seronegative spondyloarthropathies.
Ann Rheum Dis, 53 (1994), pp. 755-758
[33.]
G. Vargas-Alarcón, J. Granados, C. Bekker, J. Alcocer-Varela, D. Alarcón-Segovia.
Association of HLA-DR5 (possibly DRB1*1201) with the primary antiphospholipid syndrome in Mexican patients.
Arthritis Rheum, 38 (1995), pp. 1340-1341
[34.]
C. Johansson, C. Castillejo-López, B. Johanneson, E. Svenungsson, I. Gunnarsson, J. Frostegard, et al.
Association analysis with microsatellite and SNP markers does not support the involvement of BCL-2 in systemic lupus erythematosus in Mexican and Swedish patients and their families.
Genes Immun, 1 (2000), pp. 380-385
[35.]
M.H. Cardiel, M. Abello-Banfi, R. Ruiz-Mercado, D. Alarcón-Segovia.
How to measure health status in rheumatoid arthritis in non-English speaking patients: validation of a Spanish version of the Health Assessment Questionnaire Disability Index (Spanish HAQ-DI).
Clin Exp Rheumatol, 11 (1993), pp. 117-121
[36.]
B.A. Pons-Estel, L.J. Catoggio, M.H. Cardiel, E.R. Soriano, S. Gentiletti, A.R. Villa, Grupo Latinoamericano de Estudio del Lupus, et al.
The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among “Hispanics”.
Medicine (Baltimore), 83 (2004), pp. 1-17
[37.]
D. Alarcón-Segovia.
Descriptions of therapeutic arthrocenthesis and of synovial fluid in a Nahuatl text from prehispanic Mexico.
Ann Rheum Dis, 39 (1980), pp. 291-293
[38.]
D. Alarcón-Segovia, A. Laffon, J. Alcocer-Varela.
Probable depiction of juvenile arthritis by Sandro Botticelli.
Arthritis Rheum, 26 (1983), pp. 1266-1268
[39.]
D. Alarcón-Segovia.
Letter: Pre-Columbian representation of Heberden's nodes.
Arthritis Rheum, 19 (1976), pp. 125-126
Copyright © 2005. Elsevier España S.L. Barcelona
